MX2021008604A - Arn terapeutico para tumores solidos cancerigenos en etapa avanzada. - Google Patents
Arn terapeutico para tumores solidos cancerigenos en etapa avanzada.Info
- Publication number
- MX2021008604A MX2021008604A MX2021008604A MX2021008604A MX2021008604A MX 2021008604 A MX2021008604 A MX 2021008604A MX 2021008604 A MX2021008604 A MX 2021008604A MX 2021008604 A MX2021008604 A MX 2021008604A MX 2021008604 A MX2021008604 A MX 2021008604A
- Authority
- MX
- Mexico
- Prior art keywords
- solid tumor
- cell death
- programmed cell
- tumor cancers
- advanced stage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Esta descripción se refiere al campo de los ARN terapéuticos para el tratamiento de sujetos en los que ha fracasado, o se han vuelto intolerantes, resistentes, o refractarios a, una terapia anti-muerte celular programada 1 (PD-1) o anti-ligando 1 de muerte celular programada 1 (PD-L1), incluyendo terapia innata y adquirida PD-1 y/o PD-L1, así como en sujetos con tumor sólido cancerígeno en etapa avanzada, no extirpable, o metastásico con o sin fracaso, intolerancia, resistencia, o refractariedad a una terapia antimuerte celular programada 1 (PD-1) o anti-ligando 1 de muerte celular programada 1 (PD-L1).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962794889P | 2019-01-21 | 2019-01-21 | |
US201962926384P | 2019-10-25 | 2019-10-25 | |
EP19306461 | 2019-11-12 | ||
PCT/US2020/014019 WO2020154187A1 (en) | 2019-01-21 | 2020-01-17 | Therapeutic rna for advanced stage solid tumor cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008604A true MX2021008604A (es) | 2021-10-26 |
Family
ID=69582158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008604A MX2021008604A (es) | 2019-01-21 | 2020-01-17 | Arn terapeutico para tumores solidos cancerigenos en etapa avanzada. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220040218A1 (es) |
EP (1) | EP3914354A1 (es) |
JP (1) | JP2022518235A (es) |
KR (1) | KR20210119451A (es) |
CN (1) | CN113557060A (es) |
AU (1) | AU2020211584A1 (es) |
BR (1) | BR112021013887A2 (es) |
CA (1) | CA3125773A1 (es) |
IL (1) | IL284646A (es) |
MX (1) | MX2021008604A (es) |
SG (1) | SG11202107395VA (es) |
TW (1) | TW202043273A (es) |
WO (1) | WO2020154187A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110337305A (zh) | 2017-02-28 | 2019-10-15 | 赛诺菲 | 治疗性rna |
JP2022518236A (ja) * | 2019-01-21 | 2022-03-14 | サノフイ | 進行期固形腫瘍がんに対する治療用rnaおよび抗pd1抗体 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1673387B1 (en) * | 2003-10-10 | 2010-09-15 | Novo Nordisk A/S | Il-21 derivatives |
WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
CA3054289A1 (en) * | 2017-02-21 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
CN110337305A (zh) * | 2017-02-28 | 2019-10-15 | 赛诺菲 | 治疗性rna |
WO2020041655A1 (en) * | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
JP2022518236A (ja) * | 2019-01-21 | 2022-03-14 | サノフイ | 進行期固形腫瘍がんに対する治療用rnaおよび抗pd1抗体 |
AU2020454690A1 (en) * | 2020-06-22 | 2023-02-02 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and combinations for use in the treatment of cancer |
CN117043193A (zh) * | 2021-02-11 | 2023-11-10 | 瑞泽恩制药公司 | 通过施用新辅助pd-1抑制剂治疗癌症的方法 |
WO2023086459A2 (en) * | 2021-11-12 | 2023-05-19 | The Brigham And Women's Hospital, Inc. | Gene editing and engineering stem cells for drug delivery |
-
2020
- 2020-01-17 CN CN202080010320.9A patent/CN113557060A/zh active Pending
- 2020-01-17 TW TW109101807A patent/TW202043273A/zh unknown
- 2020-01-17 EP EP20705266.3A patent/EP3914354A1/en active Pending
- 2020-01-17 KR KR1020217026314A patent/KR20210119451A/ko unknown
- 2020-01-17 MX MX2021008604A patent/MX2021008604A/es unknown
- 2020-01-17 AU AU2020211584A patent/AU2020211584A1/en not_active Abandoned
- 2020-01-17 JP JP2021541606A patent/JP2022518235A/ja active Pending
- 2020-01-17 SG SG11202107395VA patent/SG11202107395VA/en unknown
- 2020-01-17 CA CA3125773A patent/CA3125773A1/en active Pending
- 2020-01-17 WO PCT/US2020/014019 patent/WO2020154187A1/en active Application Filing
- 2020-01-17 BR BR112021013887-0A patent/BR112021013887A2/pt not_active Application Discontinuation
-
2021
- 2021-07-06 IL IL284646A patent/IL284646A/en unknown
- 2021-07-20 US US17/380,249 patent/US20220040218A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020211584A1 (en) | 2021-08-26 |
US20220040218A1 (en) | 2022-02-10 |
KR20210119451A (ko) | 2021-10-05 |
BR112021013887A2 (pt) | 2021-09-21 |
JP2022518235A (ja) | 2022-03-14 |
EP3914354A1 (en) | 2021-12-01 |
TW202043273A (zh) | 2020-12-01 |
CA3125773A1 (en) | 2020-07-30 |
SG11202107395VA (en) | 2021-08-30 |
CN113557060A (zh) | 2021-10-26 |
WO2020154187A1 (en) | 2020-07-30 |
IL284646A (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008605A (es) | Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado. | |
Chen et al. | Sargassum fusiforme polysaccharides inhibit VEGF-A-related angiogenesis and proliferation of lung cancer in vitro and in vivo | |
MX2022007140A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
MX2016007111A (es) | Inhibidores de tirosina quinasa de bruton. | |
WO2020227159A3 (en) | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
NZ717490A (en) | Methods of treating cancer | |
MX2021008604A (es) | Arn terapeutico para tumores solidos cancerigenos en etapa avanzada. | |
MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
EA202091539A1 (ru) | Комбинированная терапия против злокачественной опухоли антагонистом iap и молекулой против pd-1 | |
AU2018271862A1 (en) | Combination therapy | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
EP4378530A3 (en) | Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody | |
MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
MX2022007516A (es) | Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. | |
MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
MX2020006808A (es) | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. |